Study finds Pfizer COVID-19 pill had no benefit in middle-age adults

Paxlovid, the COVID-19 antiviral pill developed by Pfizer that was once celebrated as a "game-changer" for the pandemic

By The Blaze —— Bio and Archives--August 27, 2022

Health and Medicine | Comments | Back To Full Article

Paxlovid, the COVID-19 antiviral pill developed by Pfizer that was once celebrated as a "game-changer" for the pandemic, has little to no benefit for younger adults, while it still appears to reduce the risk of hospitalization or death for high-risk seniors, according to a new study published Wednesday. “Among patients 65 years of age or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir than among those who did not,” the study published in the New England Journal of Medicine stated. "No evidence of benefit was found in younger adults."-- More...

#Paxlovid with zero benefit in those aged <65yo with #covid19 in new @NEJM retrospective case-control study of 109,254.
Yes, a statistical benefit in >65yo (which is the headline), but no NNT mentioned. Cost might be $1/2Mil to prevent 1 hospitalization.https://t.co/m9DyGpMRJg
— David Boulware, MD MPH (@boulware_dr) August 24, 2022

Read Full Article...

Welcome to CFP’s Comment Section!

The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.

Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.

Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.

We ask only that commenters keep it civil, keep it clean.

Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.

READ OUR Commenting Policy

Study finds Pfizer COVID-19 pill had no benefit in middle-age adults

Paxlovid, the COVID-19 antiviral pill developed by Pfizer that was once celebrated as a "game-changer" for the pandemic

Welcome to CFP’s Comment Section!

CFP Disqus Comments